What is APLS's health score?

Apellis Pharmaceuticals, Inc. (APLS) has a TradeApes health score of 68 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is APLS's estimated fair value?

Based on our 5-year discounted cash flow model, Apellis Pharmaceuticals, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is APLS undervalued or overvalued?

Our model currently rates APLS as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for APLS... Refresh in a moment for the full analysis.

Apellis Pharmaceuticals, Inc. (APLS)

Healthcare Inconclusive inconclusive healthy

$41.03

Updated: 2026-06-05

TradeApes Score

Financial Strength

85 Strong

Operating Trend

85 Strong

Relative Value

50 Mixed

Capital Allocation

35 Weak

Risk

80 Strong

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Low FCF yield — below 1%, price implies exceptional future growth

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.